Literature DB >> 10211102

Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.

B Friedrich1, K Jung, M Lein, I Türk, B Rudolph, G Hampel, D Schnorr, S A Loening.   

Abstract

Elevated activities of cysteine proteinases, the cathepsins B, H, L (CB, CH, CL) and diminished cysteine protease inhibitors (CPI) have been demonstrated in a variety of tumours and have been suggested to contribute to invasion and metastasis. The situation for prostate cancer is still unknown. In this study, using fluorimetric assays, the catalytic activities of CB, CH, CL were measured in prostatic tissue samples after radical prostatectomy, adenomectomy, transurethral resection of the prostate, in cell cultures grown from cancerous and non-cancerous parts of human prostate after prostatectomy and in the cell lines LNCaP, DU 145 and PC 3. CPIs were determined using heat activation before testing their inhibitory activity against purified CB. Comparing matched pairs of normal and cancerous tissue samples from the prostate, significantly decreased levels of CB, CL in malignant parts of the prostate were found. In contrast, primary cell cultures from cancerous samples showed elevated levels of CB, CH, CL and increased ratios of cathepsins to CPI compared with cell cultures from normal prostate. Established cell lines showed a similar distribution pattern of each cathepsin, DU 145 containing the highest levels, followed by LNCaP and PC 3. Our results suggest that elevated cathepsin levels and consequently increased ratios of cathepsins to CPI in primary cell cultures from cancerous versus non-cancerous parts of the prostate may be indicative of a cellular proteolytic imbalance in prostatic cancer cells. In this respect, primary cell culture experiments should be preferred to determinations in tissue samples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211102     DOI: 10.1016/s0959-8049(98)00273-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L.

Authors:  Matthew Huisman; Jacob P Kodanko; Karan Arora; Mackenzie Herroon; Marim Alnaed; John Endicott; Izabela Podgorski; Jeremy J Kodanko
Journal:  Inorg Chem       Date:  2018-06-08       Impact factor: 5.165

3.  Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics.

Authors:  Young Ah Goo; Alvin Y Liu; Soyoung Ryu; Scott A Shaffer; Lars Malmström; Laura Page; Liem T Nguyen; Catalin E Doneanu; David R Goodlett
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

4.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

5.  Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2013-06-09       Impact factor: 5.150

6.  Protective role of cathepsin L in mouse skin carcinogenesis.

Authors:  Fernando Benavides; Carlos Perez; Jorge Blando; Oscar Contreras; Jianjun Shen; Lisa M Coussens; Susan M Fischer; Donna F Kusewitt; John DiGiovanni; Claudio J Conti
Journal:  Mol Carcinog       Date:  2011-05-02       Impact factor: 4.784

7.  Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.

Authors:  Bong-Seop Lee; Manabu Fujita; Natalya M Khazenzon; Kolja A Wawrowsky; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

8.  Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells.

Authors:  Zala Jevnikar; Matija Rojnik; Polona Jamnik; Bojan Doljak; Urša Pečar Fonovic; Janko Kos
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

9.  Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.

Authors:  Matija Rojnik; Zala Jevnikar; Bojana Mirkovic; Damjan Janes; Nace Zidar; Danijel Kikelj; Janko Kos
Journal:  Radiol Oncol       Date:  2011-10-08       Impact factor: 2.991

10.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.